GCG and hyperlipidemia: One such previous study indicated possible cardiac benefits (possibly mediated through GLP-1) and showed that DPP-4 inhibitors may also have direct effects on the heart and on cardiovascular risk factors (such as hypertension and hyperlipidaemia), independent of the incretin system (Zhang et al., 2019).